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Abstract
Complex karyotype (CK) with ≥3 abnormalities is detected in 10-12% of patients with acute 
myeloid leukemia (AML) and associated with poor prognosis. The most common unbalanced 
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abnormalities found in CK result in loss of material from the 5q, 7q and/or 17p chromosome arms. 
The presence of 5q, 7q and/or 17p abnormalities denotes typical CK and their absence denotes 
atypical CK. Since molecular features of CK-AML are not well-characterized, we investigated 
mutational status of 81 leukemia/cancer-associated genes in 160 clinically well-characterized 
patients. They included 136 patients with ≥3 exclusively unbalanced chromosome abnormalities, 
96 of whom had a typical CK and 40 atypical CK, and 24 patients with ≥1 balanced abnormality 
in addition to ≥2 unbalanced ones. Patients with atypical CK-AML differed from those with 
typical CK-AML: they carried TP53 mutations less often (P<0.001) and more often PHF6 
(P=0.008), FLT3-TKD (P=0.02), MED12 (P=0.02) and NPM1 (P=0.02) mutations. They were 
younger (P=0.007), had higher WBC (P=0.001) and percentages of marrow (P<0.001) and blood 
(P=0.006) blasts, higher complete remission rates (P=0.02) and longer overall survival (P<0.001), 
thus indicating that atypical and typical CK-AMLs constitute distinct disease subtypes. We also 
identified smaller patient subsets within both typical and atypical CK-AML that differed 
molecularly and clinically.
Keywords
acute myeloid leukemia; complex karyotype; next-generation sequencing; gene mutations; clinical 
outcome
INTRODUCTION
Patients with acute myeloid leukemia (AML) presenting with a complex karyotype (CK), 
defined as a karyotype with ≥3 chromosome abnormalities, comprise 10-12% of all AML 
patients and thus constitute the second largest (following cytogenetically normal AML) 
cytogenetic subset of AML patients.1–4 In most studies, the definition of CK excludes 
karyotypes consisting of ≥3 abnormalities that include t(8;21)(q22;q22), inv(16)(p13q22)/
t(16;16)(p13;q22), t(15;17)(q22;q12-21), t(9;11)(p22;q23), any balanced rearrangement 
involving band 11q23, or any “primary balanced abnormality”.2,3,5–10 Additionally, the 2017 
European LeukemiaNet (ELN) recommendations11 also exclude from the CK category 
karyotypes containing such World Health Organization (WHO)-designated recurring 
translocations or inversions as t(6;9)(p23;q34), inv(3)(q21q26)/t(3;3)(q21;q26) and t(9;22)
(q34;q11.2).
Although each chromosome in the human karyotype can participate in various structural and 
numerical abnormalities constituting CK in AML, the involvement of particular 
chromosomes or chromosome arms in these aberrations is non-random.7,12,13 Unbalanced 
abnormalities predominate and mostly result in loss of chromosome segments. The most 
commonly lost are parts of the long arm of chromosome 5 (5q), detected in ~80% of patients 
with CK-AML, followed by loss of material from 7q and 17p, each occurring in 
approximately one-half of the cases.13 Abnormalities of 5q, 7q and 17p often occur together, 
and ~85% of all patients with CK-AML harbor at least one of these abnormalities. Based on 
these data, we have divided CKs into typical and atypical categories, with the former defined 
as CK with ≥3 abnormalities that include 5q, 7q and/or 17p loss, and the latter as CK with 
≥3 abnormalities other than the aforementioned ones.13,14
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Despite being the second largest cytogenetic subset of AML, CK-AML is relatively poorly 
characterized at the molecular level. The high incidence of TP53 mutations and their adverse 
influence on CK-AML patients’ outcome are well-known,8,13,15–17 but information on the 
mutational involvement of other genes has only recently begun to be collected as part of 
studies using next-generation sequencing (NGS) in large series of AML patients.18–20 To our 
knowledge, no large NGS study has focused specifically on molecular characterization of 
CK-AML.
Therefore, we analyzed mutational status of 81 leukemia/cancer-associated genes and 
clinical characteristics of a clinically well-characterized cohort of 160 CK-AML patients. 
Our data show that patients with typical and atypical CKs differ with regard to their 
mutational patterns, clinical features and outcome, and thus should be considered as separate 
disease subtypes.
METHODS
Patients, treatment, and cytogenetic studies
Among 1602 adults diagnosed with de novo AML (other than acute promyelocytic 
leukemia) whose pretreatment bone marrow (BM) or blood samples were subjected to NGS 
analysis,14 we identified 208 patients with ≥3 chromosome abnormalities. However, based 
on the 2017 ELN recommendations,11 we excluded 48 patients with ≥3 abnormalities that 
included the WHO-designated recurring balanced abnormalities, thus leaving 160 patients 
with CK-AML who are the subject of this study (Figure 1).
All 160 patients were enrolled onto Cancer and Leukemia Group B (CALGB) front-line 
treatment protocols,21–34 and all patients, except nine,34 received intensive induction with 
cytarabine and an anthracycline (for details see Supplementary Information). CALGB is 
now part of the Alliance for Clinical Trials in Oncology (Alliance). The median follow-up 
time for living patients was 6.8 years (range, 3.2-10.2). All protocols were approved by the 
institutional review board of each participating institution, and written informed consent for 
the research use of their specimens was obtained from all patients before enrollment in 
accordance with the Declaration of Helsinki.
Cytogenetic analyses were performed by the CALGB/Alliance-approved institutional 
laboratories. Pretreatment BM and/or blood samples were subjected to short-term (24- to 48-
hour) unstimulated cultures, and karyotypes were interpreted according to the International 
System for Human Cytogenetic Nomenclature.35 All results were reviewed centrally.36
Subsets of complex karyotype
Based on the presence or absence of specific chromosome abnormalities, we discerned 
subsets of CK (Figure 1). First, we separated CKs that included ≥1 non-WHO-designated 
balanced abnormalities (e.g., reciprocal translocations, inversions; n=24), either known to be 
recurrent37 (n=9) or hitherto not reported in the literature37 (n=15; thereafter referred to as 
“unique”), from CKs containing exclusively unbalanced abnormalities (n=136). We did this 
because balanced chromosome abnormalities are considered to represent primary 
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chromosome abnormalities and almost always create gene fusions that play a pivotal role in 
leukemogenesis.
Among patients with CK with only unbalanced chromosome abnormalities (n=136), we 
identified 96 patients who had a typical CK, that is, CK containing abnormalities leading to 
loss of material from 5q, 7q and/or 17p. The remaining 40 patients had an atypical CK, in 
which no abnormality resulted in 5q, 7q or 17p loss.
Within the atypical CK category (n=40), we recognized two subtypes. Karyotypes of the 
first (n=15) contained numerical abnormalities, either exclusively (n=11) or predominantly 
(n=4); each of the four patients with predominantly numerical aberrations had only one 
unbalanced structural abnormality, which in three patients was found in only one of three or 
four abnormal clones. Thereafter, we refer to this subset as “atypical CK with numerical 
abnormalities”. The second atypical CK subset (n=25), which we thereafter refer to as “other 
atypical CK”, comprised patients with a mixture of structural and numerical aberrations, 
with the former usually being more numerous.
Finally, to perform exploratory analyses, we identified seven subtypes within the typical CK 
category (n=96), which were defined by combinations of 5q, 7q and 17p abnormalities 
(Figure 1).
Molecular analyses
Mononuclear cells were enriched through Ficoll-Hypaque gradient centrifugation and 
cryopreserved until use. Genomic DNA was extracted using the DNeasy Blood and Tissue 
Kit (QIAGEN, Hilden, Germany). The mutational status of 80 protein-coding genes was 
established centrally at The Ohio State University by targeted amplicon sequencing using 
two separate gene panels on the MiSeq platform (Illumina, San Diego, CA). Details of the 
assay and genes included in the panels are provided in the Supplementary Information. 
Because of sample availability, the mutational status of the NF1 gene was determined in 90 
patients. The data were analyzed using the MuCor program,38 followed by visual inspection 
and quality control of the BAM files. The gene mutation status was deemed to be not 
evaluable if <15 reads were present. Variants (missense, nonsense or frameshift) were 
considered to be mutations if they were not reported in the 1000 Genome or dbSNP142 
databases. Only variants occurring with variant allele fraction (VAF) ≥0.10 were included in 
the analyses. In addition to 80 genes analyzed by NGS, the CEBPA mutational status was 
determined as previously described,39 thus bringing the total number of genes analyzed to 
81. Only patients harboring biallelic CEBPA mutations were considered to be mutated.11 
Testing for internal tandem duplication of the FLT3 gene (FLT3-ITD) was performed as 
described previously.40
The presence of copy number variations in the 17p chromosome arm was determined by 
genotyping of the available patient samples (n=121) using Illumina Omni-Express single 
nucleotide polymorphism (SNP) arrays, followed by analysis with Illumina GenomeStudio 
plugin cnvpartition v3.2.0. Copy-neutral loss of heterozygosity (CN-LOH) was set to 1Mb.
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Statistical analyses
Baseline characteristics were compared using the two-sided Fisher’s exact test for 
categorical variables and two-sided Wilcoxon rank-sum test for continuous variables.41 All 
other P-values were from one-sided tests. A P-value of <0.05 was considered statistically 
significant. Outcome analyses included only patients who did not undergo allogeneic stem-
cell transplantation in first complete remission (CR) (n=136). Disease-free survival (DFS) 
was measured from the CR date until the date of relapse or death from any cause, and 
relapse-free patients were censored at last follow-up. Overall survival (OS) was measured 
from the date on study until the date of death from any cause; patients alive at last follow-up 
were censored. For multivariable analyses, we used stepwise logistic regression for 
modeling CR achievement and Cox proportional hazard stepwise regression for modeling 
DFS and OS. The dataset was locked on July 27, 2017. Data collection and statistical 
analyses were performed by the Alliance Statistics and Data Center using SAS 9.4.
RESULTS
Mutational landscape of all patients with CK-AML
In the entire cohort of 160 patients, we detected 359 mutations in 59 of 81 genes analyzed, 
with a median of two mutations per patient (range, 0-7). No patient with CK-AML had a 
mutation in any of the following 22 genes analyzed: ARAF, ATM, BCL2, BRAF, CBL, 
CCND2, CSNK1A1, GATA1, IKZF3, JAK2, KLHL6, MAPK1, MYD88, PIK3CD, 
PLEKHG5, PRKD3, RAD21, SF3A1, TGM7, U2AF2, XPO1 or ZMYM3.
As expected, the most often mutated gene was TP53, whose mutations were detected in 81 
of 160 patients (51%). Other recurrent mutations were less common, with the most frequent 
being mutations in the TET2 (n=24, 15% of the entire patient cohort), DNMT3A (n=19, 
12%), NF1 (n=10, 11% of 90 patients analyzed), NRAS (n=15, 9%), IDH2 (n=12, 8%), 
RUNX1 (n=12, 8%), NPM1 (n=11, 7%), SRSF2 (n=10, 6%), ZRSR2 (n=10, 6%), ASXL1 
(n=8, 5%) and PHF6 (n=8, 5%) genes, and FLT3-ITD (n=8, 5%). However, the 
aforementioned and other, less common mutations were not uniformly distributed among 
CK subsets, and major differences in frequencies of particular gene mutations, as well as in 
cytogenetic and clinical characteristics, emerged when we compared specific subsets of CK-
AML patients.
Typical versus atypical complex karyotype
In addition to abnormalities of 5q, 7q and 17p, whose presence or absence have been used to 
define, respectively, typical and atypical CK-AML, these CK categories also differed with 
regard to the degree of karyotype complexity, with atypical CKs containing fewer 
cytogenetic abnormalities than typical CKs (median, 4 vs 9 abnormalities; P<0.001).
On the other hand, there was no significant difference in the number of gene mutations per 
patient between patients with atypical and those with typical CK-AML (P=0.23; Table 1). 
Regarding particular gene mutations, the most striking difference between the CK categories 
was the rarity of TP53 mutations in patients with atypical CK-AML (4 of 40 patients, 10%) 
as opposed to their presence in most patients with typical CK-AML (65 of 96 patients, 67%; 
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P<0.001). Moreover, when present in atypical CK-AML patients, TP53 mutations had lower 
VAFs than TP53 mutations found in patients with typical CK-AML (Supplementary Figure 
S1). The difference between atypical and typical CK-AML was even more evident when we 
also considered genomic rearrangements of 17p encompassing the TP53 locus, mostly losses 
of 17p material but also CN-LOH. Among patients with a successful SNP array analysis 
(including 69 patients with typical and 33 with atypical CK-AML), an alteration of TP53 
(i.e., TP53 mutation and/or loss of TP53 locus or CN-LOH) was detected in 88% of patients 
with typical but only in 15% of patients with atypical CK-AML (P<0.001; Figure 2).
In contrast, PHF6, another tumor suppressor gene,18 was more frequently mutated in 
patients with atypical than typical CK-AML (15% vs 2%; P=0.008), as were the MED12 
(8% vs 0%; P=0.02) and NPM1 (15% vs 3%; P=0.02) genes and FLT3-TKD (11% vs 1%; 
P=0.02; Table 1, Figure 3). Interestingly, all mutations in the MED12 gene (Supplementary 
Figure S2), which is located at Xq13.1, had high VAFs (0.96, 0.74, 0.51), which in two 
patients (no. 14 and 29) were markedly higher than VAFs of other detected mutations, 
suggesting that MED12 mutations may represent early mutational events, which might be 
associated with the FAB M0 morphology (patients no. 5 and 14; Supplementary Table S1). 
We also compared involvement of genes categorized into the major AML-associated 
functional groups18 and found additional differences (Supplementary Table S2). Beside 
lower incidence of mutations in tumor suppressor genes (28% vs 71%; P<0.001), mostly 
driven by paucity of TP53 mutations, patients with atypical CKs carried mutations in genes 
encoding kinases (30% vs 13%; P=0.03) and in RAS pathway genes (25% vs 9%; P=0.03) 
more often.
Clinically, patients with atypical CK-AML were younger (P=0.007; median age, 53 vs 59 
years), had higher white blood cell (WBC) counts (P=0.001; 23.8 vs 6.0×109/l), percentages 
of BM (76% vs 46%; P<0.001) and blood (59% vs 28%; P=0.006) blasts, and tended to have 
extramedullary involvement more often (24% vs 11%; P=0.06; Table 2).
Importantly, although treatment outcomes were generally poor, atypical CK-AML patients 
had higher CR rates (59% vs 35%; P=0.02), a trend towards longer DFS (P=0.08; 3-year 
rates, 10% vs 0%; Figure 4a) and longer OS (P<0.001; 3-year rates, 24% vs 1%; Figure 4b) 
than typical CK-AML patients. In multivariable analyses, the type of CK remained 
prognostically significant for all outcome endpoints (Table 4). The differences in clinical 
outcome were also present when we considered patients aged <60 years and those aged ≥60 
years separately. In both age groups, OS of patients with atypical CK-AML was longer than 
that of patients with typical CK-AML (younger patients: P=0.005; 3-year rates, 25% vs 3%; 
older patients: P=0.002; 3-year rates, 21% vs 0%), and there were trends for patients with 
atypical CK-AML to have higher CR rates (younger patients: 60% vs 38%, P=0.11; older 
patients: 57% vs 33%, P=0.12). Younger patients with atypical CK-AML had a longer DFS 
(P=0.05; 3-year rates, 17% vs 0%), whereas DFS did not differ significantly between the 
CK-AML groups among older patients (Table 3; Supplementary Figures S3 and S4).
TP53 mutations and TP53 alterations in typical complex karyotype
Although TP53 mutations are regarded as a molecular hallmark of patients with CK-AML,
8,13,15–17
 they do not occur in all patients and, as shown above, are most frequent in patients 
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with typical, but rare in those with atypical, CK-AML. However, even among typical CK-
AML patients, approximately one-third do not harbor TP53 mutations. Thus, we compared 
cytogenetic, molecular and clinical features between typical CK-AML patients with and 
without TP53 mutations.
Cytogenetically, TP53-mutated patients (n=65) had more complex karyotypes (P=0.02; 
median, 10 vs 7 chromosome abnormalities), and more often harbored 5q (89% vs 48%, 
P<0.001) and 17p (78% vs 55%, P=0.03), but not 7q (63% vs 71%, P=0.50), abnormalities 
than patients with wild-type TP53 (n=31). Molecularly, patients with wild-type TP53 more 
often carried BCOR mutations (13% vs 2%; P=0.04), and were the only ones with mutations 
in SMARCA2 and PLCG2 (Supplementary Table S3). Clinically, TP53-mutated patients 
were older (P=0.008; median age, 63 vs 54 years) and tended to be less frequently male 
(57% vs 77%; P=0.07). Although their CR rates and DFS were similar, patients with TP53 
mutations had shorter OS than those without (P=0.003; Supplementary Table S4).
TP53 mutations often coexist with genomic abnormalities of 17p, such as deletions of a 
normal copy of TP53, resulting in the hemizygous TP53 mutation, or a homologous 
recombination involving 17p that results in uniparental disomy and homozygous TP53 
mutations.8 TP53 mutations and/or genomic losses (hereafter named TP53 alterations) were 
shown to be the most important prognostic factor in patients with CK-AML.8 However, 
Rücker et al.8 did not distinguish between typical and atypical CK-AML. Our analysis has 
revealed that TP53 alterations are also associated with shorter OS (P<0.001; 3-year rates, 
0% vs 13%; Supplementary Table S5) when only typical CK-AML patients are analyzed. 
Moreover, patients without TP53 alterations had less complex karyotypes (P<0.001; median, 
4 vs 10 chromosome abnormalities) and more often harbored mutations in NPM1, WT1, 
BCOR and FLT3-ITD (Supplementary Table S6).
Atypical complex karyotypes with numerical abnormalities versus other atypical complex 
karyotypes
Within the atypical CK-AML category (n=40), patients with only numerical abnormalities 
(n=15) tended to carry fewer chromosome abnormalities than 25 patients with other atypical 
CK-AML (median, 3 vs 4 abnormalities; P=0.07). In the latter subset, most frequent were +8 
(found in 32% of patients) and loss of 1p (28%), 12p (24%) and 9q (20%), whereas in 
patients with only numerical abnormalities most common were +8 (60%), +4 (40%), +13 
(33%) and +21 (33%).
Molecularly, patients with numerical abnormalities had more mutations than patients with 
other atypical CK-AML (median, 3 vs 2; P=0.03), and they were the only ones harboring 
mutations in RUNX1, ASXL1, SRSF2, KRAS and STAG2. In contrast, TP53 mutations, 
generally infrequent in atypical CK-AML, were found exclusively in patients with other 
atypical CK-AML (Figure 3, Supplementary Table S7).
There were no significant differences in pretreatment characteristics between the subsets, 
except for lower platelet counts in patients with numerical abnormalities (P=0.009; median 
32 vs 69 × 109/l). Likewise, CR rates, DFS and OS of patients in both subsets of atypical 
CK-AML were not significantly different (Supplementary Table S8).
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Typical CK with abnormalities of 7q, but not of 5q or 17p, differs from typical CKs with 
other combinations of 5q, 7q and 17p abnormalities
We performed exploratory analyses of seven subtypes of typical CK-AML delineated by 
combinations of 5q, 7q and 17p abnormalities. Although most of these subtypes were 
similar, patients with only 7q abnormalities (n=11) turned out to constitute a subtype that 
differed cytogenetically, molecularly and clinically from the remaining patients combined 
(n=85; Supplementary Tables S9 and S10). Karyotypes of patients with only 7q 
abnormalities contained fewer chromosome abnormalities (P<0.001; median, 5 vs 10), but 
several gene mutations were more frequent in these patients. Specifically, more common 
were FLT3-ITD and mutations in BCOR, WT1, DNMT3A, NPM1 and RUNX1. In contrast, 
TP53 mutations were much less frequent in this typical CK-AML subtype than in patients 
with other combinations of 5q, 7q and 17p abnormalities (18% vs 74%; P<0.001; 
Supplementary Table S9). Additionally, among patients with SNP array data available, none 
of eight patients with only 7q abnormalities had submicroscopic genomic alterations of 17p 
involving the TP53 locus. In contrast, among the remaining typical CK-AML patients, seven 
of 12 (58%; P=0.01) patients without cytogenetically detectable 17p abnormalities carried 
submicroscopic 17p alterations uncovered by SNP array analysis.
Moreover, patients with only 7q abnormalities were younger (P=0.04; median age, 49 vs 61 
years), had lower platelet counts (P=0.03; median, 32 vs 53 × 109/l) and higher WBC counts 
(P=0.05; median, 15.7 vs 5.5 × 109/l) and percentages of BM blasts (68% vs 44%; P=0.02; 
Supplementary Table S10). Although CR rates were not significantly different (50% vs 33%; 
P=0.31), OS of patients with only 7q abnormalities was longer than OS of the remaining 
patients with typical CK-AML (P<0.001; 3-year rates, 10% vs 0%; Supplementary Figure 
S5).
Complex karyotypes containing balanced chromosome abnormalities: rare recurrent 
versus unique abnormalities
The most striking feature of a small group of patients with CK-AML with a rare recurrent 
balanced chromosome abnormality was a paucity of gene mutations. Four of nine patients in 
this group did not carry a single mutation in any of the 81 genes analyzed, and the number of 
mutations was lower than that in 15 patients with CK-AML with a unique (i.e., not 
previously reported) balanced abnormality (median, 1 vs 2; Supplementary Figure S6 and 
Table S11). Only the TP53 mutation was recurrent, detected in three (33%) patients. 
Although there were no significant differences in outcome or most pretreatment features 
(data not shown) between CK-AML patients with a rare recurrent balanced abnormality and 
those with unique balanced aberrations, the latter were older (median, 61 vs 39 years; 
P=0.05). Their karyotypes tended to be more complex (median, 9 vs 5 abnormalities), and 
contained abnormalities of 5q, 7q and/or 17p in almost three-fourths of these patients.
When we compared clinical outcome (Supplementary Table S12) and the distribution of 
gene mutations (Supplementary Table S13) between CK-AML patients with unique 
balanced aberrations and patients with typical CK-AML with exclusively unbalanced 
abnormalities, we found no significant differences (with a single exception of SF3B1 
mutations being more frequent in CK-AML with unique balanced aberrations). These data 
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suggest that patients with a unique balanced aberration should not be prevented from being 
classified in the typical CK-AML category.
DISCUSSION
The salient finding of our study is the demonstration that patients with typical and atypical 
CK-AML differ considerably with regard to mutation patterns, pretreatment characteristics 
and clinical outcome. Remarkably, TP53 mutations, considered to constitute a hallmark of 
complex karyotypes in AML,8,13–18 were virtually absent in patients with atypical CK-
AML, and, when present, had relatively low VAFs. Instead, atypical CK-AML patients 
carried more often PHF6, NPM1 and MED12 mutations and FLT3-TKD, which were either 
very rare (PHF6, NPM1, FLT3-TKD) or not observed at all (MED12) in patients with 
typical CK-AML. Moreover, patients with atypical CK-AML had more frequently mutations 
in genes comprising such functional groups as kinases and the RAS pathway, thus 
underscoring the fact that atypical and typical CKs differ profoundly with respect to their 
genetic make-up.
Somatic mutations in the MED12 gene, which encodes a subunit of the Mediator complex 
that plays a vital role in regulation of transcription of most protein-coding genes, have been 
reported to be recurrent in and associated with markers of poor prognosis in chronic 
lymphocytic leukemia,42 but, to date, rarely detected in AML.14 Although MED12 
mutations were infrequent, their VAFs were higher than VAFs of all other mutations found 
in two patients and higher than the VAF of the TP53 mutation in the third, indicating that 
MED12 mutations represent early and pathogenetically important mutational events. 
Identification of more patients with atypical CK-AML carrying MED12 mutations is 
necessary to confirm their potential association with FAB M0 morphology (detected in two 
of three patients) or to determine whether MED12 mutations have prognostic significance.
In addition to dissimilar cytogenetic and molecular characteristics, patients with atypical 
CK-AML had better clinical outcome than those with typical CK-AML in the entire patient 
cohort, both in univariable and multivariable analyses, and also when we considered younger 
and older patients separately. This is likely associated with a marked difference in the 
incidence of TP53 alterations between CK-AML types, and further supports the notion that 
atypical and typical CK-AML constitute distinct disease subtypes, which should be 
considered independently in search of potential therapeutic targets. It is thus possible that 
patients with atypical CK-AML are less likely to respond to treatment regimens shown to be 
more efficacious in AML patients with TP53 mutations.43,44
Within the atypical CK-AML category, two subsets (i.e., numerical and other CK-AML) 
differed in frequencies of specific mutations, with RUNX1, ASXL1, SRSF2, KRAS and 
STAG2 mutations occurring exclusively in patients with atypical CK with numerical 
abnormalities, but infrequent TP53 mutations found only in patients with the other atypical 
CK-AML. However, there were essentially no clinical differences between the subsets.
This was not the case for a small subset of typical CK-AML characterized cytogenetically 
by the presence of 7q but not 5q or 17p abnormalities. Patients in this subset had longer OS 
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than other patients with typical CK-AML, which may have been in part associated with their 
younger age and the presence of favorable molecular findings such as a lower incidence of 
TP53 mutations, absence of submicroscopic genomic alterations involving the TP53 locus or 
a higher frequency of NPM1 mutations. These patients also had adverse features such as 
lower platelet and higher WBC counts, and higher frequency of FLT3-ITD and WT1 and 
RUNX1 mutations. However, since the number of patients with only 7q abnormalities was 
very small, these results require corroboration.
We grouped CK-AML patients harboring balanced abnormalities such as reciprocal 
translocations or inversions, either known to be recurrent or unique, i.e., hitherto not 
reported in the literature, into a separate category. Our preliminary results seem to support 
this approach for most CK-AML patients with rare recurrent balanced abnormalities, who 
either do not harbor any or have very few gene mutations in addition to their balanced 
chromosome abnormality, and infrequently carry TP53 mutations. This resembles findings 
of others18,45 and ours14,46 in patients with balanced rearrangements involving 11q23/
KMT2A(MLL), who have very few gene mutations. It is possible that once more cases with 
such currently rare recurrent balanced abnormalities as t(8;16)(p11.2;p13.3), t(12;22)
(p13;q12) or t(10;11)(p13;q21), each present in one patient in our series, are reported in the 
literature, these chromosome abnormalities will be recognized by the WHO classification as 
denoting specific clinico-pathologic entities of AML. When this happens, the presence of the 
aforementioned recurrent balanced abnormalities in patients with ≥3 abnormalities will 
automatically exclude such patients from the CK-AML category akin to the current WHO-
designated reciprocal translocations or inversions.11
In contrast, patients with CK-AML with a unique reciprocal translocation or inversion had 
both cytogenetic and molecular findings resembling those found in typical CK-AML 
patients (including a high frequency of TP53 alterations), suggesting that the presence of 
unique balanced abnormalities should not exclude these patients from the typical CK-AML 
category.
In summary, we show that CK-AML is heterogeneous cytogenetically, clinically and at the 
molecular level. Our data provide rationale for separating patients with typical from those 
with atypical CK-AML since their outcomes differ when current chemotherapeutic regimens 
are used, and potential targeted therapies will likely be different because of their vastly 
dissimilar molecular genetic backgrounds.
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Figure 1. 
Overview of the study design. AML denotes acute myeloid leukemia; CALGB, Cancer and 
Leukemia Group B; CK, complex karyotype; NGS, next-generation sequencing.
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Figure 2. 
Distribution of the combinations of TP53 mutations and 17p genomic rearrangements 
(determined using SNP arrays) in subsets of patients with acute myeloid leukemia (AML) 
and a complex karyotype (CK): (a) typical CK (n=69), (b) atypical CK (n=33), (c) CK with 
rare recurrent balanced chromosome abnormalities (n=9), (d) CK with unique balanced 
chromosome abnormalities (n=10). Dark blue color denotes patients with both TP53 
mutation and 17p genomic rearrangement; lighter blue, patients with TP53 mutation and no 
17p genomic rearrangement; light blue, patients with wild-type TP53 and 17p genomic 
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rearrangement present, and red color indicates patients with wild-type TP53 and no 17p 
genomic rearrangement. All patients in the first three subsets combined, indicated by the 
various shades of blue, are considered to harbor an alteration of TP53 (i.e., TP53 mutation, 
deletion of 17p resulting in loss of TP53 locus and/or copy-neutral loss of heterozygosity 
encompassing TP53 locus). Typical CK-AML (a) clearly differs from atypical CK-AML (b) 
with regard to the frequency of TP53 alterations (88% vs 15%; P<0.001).
Mrózek et al. Page 16
Leukemia. Author manuscript; available in PMC 2019 August 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Oncoprint of mutations detected in acute myeloid leukemia patients with atypical and those 
with typical complex karyotype (CK). Subsets identified within both atypical and typical CK 
are separated by thicker blue vertical lines. Each column represents an individual patient, 
and each row represents a single gene. The genes are clustered into the previously reported 
functional groups,18 with N* indicating “NPM1”. “CEBPA bi” indicates biallelic mutations 
of the CEBPA gene. Red color denotes gene mutation, darker grey, wild-type status of the 
gene, and lighter grey, mutation status not determined.
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Figure 4. 
Comparison of (a) disease-free survival and (b) overall survival of acute myeloid leukemia 
patients with typical and atypical complex karyotype (CK).
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Table 1.
Frequencies of gene mutations in patients with acute myeloid leukemia with atypical complex karyotype and 
in those with typical complex karyotype
Genea Atypical CK n=40 Typical CK n=96 P-valueb
TP53, n (%) <0.001
 Mutated 4 (10) 65 (67)
 Wild-type 36 (90) 31 (33)
TET2, n (%) 0.13
 Mutated 10 (25) 13 (14)
 Wild-type 30 (75) 83 (86)
DNMT3A, n (%) 0.41
 Mutated 7 (18) 11 (11)
  R882 2 5
  Non-R882 5 6
 Wild-type 33 (83) 85 (89)
NF1, n (%) 0.42
 Mutated 1 (5) 7 (14)
 Wild-type 21 (95) 44 (86)
NRAS, n (%) 0.18
 Mutated 6 (15) 6 (6)
 Wild-type 34 (85) 90 (94)
RUNX1, n (%) 0.75
 Mutated 4 (10) 8 (8)
 Wild-type 36 (90) 88 (92)
ZRSR2, n (%) 0.06
 Mutated 6 (15) 4 (4)
 Wild-type 34 (85) 92 (96)
IDH2, n (%) 0.48
 Mutated 4 (10) 6 (6)
 Wild-type 36 (90) 90 (94)
NPM1, n (%) 0.02
 Mutated 6 (15) 3 (3)
 Wild-type 34 (85) 90 (97)
SRSF2, n (%) 0.72
 Mutated 3 (8) 6 (6)
 Wild-type 35 (92) 88 (94)
PHF6, n (%) 0.008
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Genea Atypical CK n=40 Typical CK n=96 P-valueb
 Mutated 6 (15) 2 (2)
 Wild-type 34 (85) 94 (98)
FLT3-ITD, n (%) 0.22
 Present 4 (11) 4 (5)
 Absent 31 (89) 84 (95)
ASXL1, n (%) 0.42
 Mutated 3 (8) 4 (4)
 Wild-type 37 (93) 92 (96)
IDH1, n (%) 0.36
 Mutated 3 (8) 3 (3)
 Wild-type 37 (92) 93 (97)
BCOR, n (%) 0.67
 Mutated 1 (3) 5 (5)
 Wild-type 39 (98) 91 (95)
FLT3-TKD, n (%) 0.02
 Present 4 (11) 1 (1)
 Absent 34 (89) 93 (99)
PTPN11, n (%) 0.63
 Mutated 2 (5) 3 (3)
 Wild-type 38 (95) 93 (97)
PRKCB, n (%) 0.32
 Mutated 0 (0) 4 (4)
 Wild-type 40 (100) 92 (96)
SMARCA2, n (%) 0.32
 Mutated 0 (0) 4 (4)
 Wild-type 40 (100) 92 (96)
ETV6, n (%) 0.58
 Mutated 2 (5) 2 (2)
 Wild-type 38 (95) 94 (98)
STAG2, n (%) 0.58
 Mutated 2 (5) 2 (2)
 Wild-type 38 (95) 94 (98)
TYK2, n (%) 0.58
 Mutated 2 (5) 2 (2)
 Wild-type 38 (95) 94 (98)
WT1, n (%) 0.58
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Genea Atypical CK n=40 Typical CK n=96 P-valueb
 Mutated 2 (5) 2 (2)
 Wild-type 38 (95) 94 (98)
KIT, n (%) 1.00
 Mutated 1 (3) 3 (3)
 Wild-type 36 (97) 91 (97)
KMT2A, n (%) 1.00
 Mutated 1 (3) 3 (3)
 Wild-type 39 (98) 93 (97)
PLCG2, n (%) 1.00
 Mutated 1 (3) 3 (3)
 Wild-type 39 (98) 93 (97)
MED12, n (%) 0.02
 Mutated 3 (8) 0 (0)
 Wild-type 37 (93) 96 (100)
BRD4, n (%) 1.00
 Mutated 1 (3) 2 (2)
 Wild-type 39 (98) 94 (98)
NOTCH1, n (%) 1.00
 Mutated 1 (3) 2 (2)
 Wild-type 39 (98) 94 (98)
PIK3CG, n (%) 1.00
 Mutated 1 (3) 2 (2)
 Wild-type 39 (98) 94 (98)
SMC3, n (%) 1.00
 Mutated 1 (3) 2 (2)
 Wild-type 39 (98) 94 (98)
KRAS, n (%) 0.08
 Mutated 2 (5) 0 (0)
 Wild-type 37 (95) 96 (100)
CCND1, n (%) 0.50
 Mutated 1 (3) 1 (1)
 Wild-type 39 (98) 95 (99)
GSK3B, n (%) 0.50
 Mutated 1 (3) 1 (1)
 Wild-type 39 (98) 95 (99)
IKZF1, n (%) 0.50
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Genea Atypical CK n=40 Typical CK n=96 P-valueb
 Mutated 1 (3) 1 (1)
 Wild-type 39 (98) 95 (99)
SMC1A, n (%) 0.50
 Mutated 1 (3) 1 (1)
 Wild-type 39 (98) 95 (99)
AKT1, n (%) 1.00
 Mutated 0 (0) 2 (2)
 Wild-type 40 (100) 94 (98)
BRINP3, n (%) 1.00
 Mutated 0 (0) 2 (2)
 Wild-type 40 (100) 94 (98)
CEBPA, n (%) 1.00
 Mutated 0 (0) 2 (2)
 Wild-type 34 (100) 83 (98)
HIST1H1E, n (%) 1.00
 Mutated 0 (0) 2 (2)
 Wild-type 40 (100) 94 (98)
SETBP1, n (%) 1.00
 Mutated 0 (0) 2 (2)
 Wild-type 40 (100) 94 (98)
U2AF1, n (%) 1.00
 Mutated 0 (0) 2 (2)
 Wild-type 40 (100) 94 (98)
BCORL1, n (%) 0.29
 Mutated 1 (3) 0 (0)
 Wild-type 39 (98) 96 (100)
HNRNPK, n (%) 0.29
 Mutated 1 (3) 0 (0)
 Wild-type 39 (98) 96 (100)
IL7R, n (%) 0.29
 Mutated 1 (3) 0 (0)
 Wild-type 38 (97) 96 (100)
JAK1, n (%) 0.29
 Mutated 1 (3) 0 (0)
 Wild-type 39 (98) 96 (100)
SF3B1, n (%) 0.29
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Genea Atypical CK n=40 Typical CK n=96 P-valueb
 Mutated 1 (3) 0 (0)
 Wild-type 39 (98) 96 (100)
AXL, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 40 (100) 95 (99)
BTK, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 40 (100) 95 (99)
FBXW7, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 39 (100) 95 (99)
GATA2, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 40 (100) 95 (99)
JAK3, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 40 (100) 95 (99)
MAPK3, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 40 (100) 95 (99)
PTEN, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 40 (100) 95 (99)
RAF1, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 40 (100) 95 (99)
SAMHD1, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 40 (100) 95 (99)
SF1, n (%) 1.00
 Mutated 0 (0) 1 (1)
 Wild-type 40 (100) 95 (99)
Total number of 
mutations
0.23
 Median 3 2
 Range 0-7 0-6
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Abbreviations: CK, complex karyotype; FLT3-ITD, internal tandem duplication of the FLT3 gene; FLT3-TKD, tyrosine kinase domain mutation in 
the FLT3 gene.
aOnly genes mutated in at least one patient are listed, and they are arranged according to the frequency of mutations, from most to least frequent. 
No mutation was detected in the following genes tested: ARAF, ATM, BCL2, BRAF, CBL, CCND2, CSNK1A1, CTNNB1, EZH2, GATA1, 
IKZF3, JAK2, KLHL6, MAPK1, MYD88, PIK3CD, PLEKHG5, PRKD3, RAD21, SF3A1, SYK, TGM7, U2AF2, XPO1 and ZMYM3.
bP-values for categorical variables are from Fisher’s exact test, P-values for continuous variables are from Wilcoxon rank sum test.
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Table 2.
Comparison of pretreatment characteristics between patients with acute myeloid leukemia with typical and 
those with atypical complex karyotype
Characteristic Atypical CK n=40 Typical CK n=96 P-valuea
Age, years 0.007
 Median 53 59
 Range 18-77 30-84
Sex, n (%) 0.23
 Male 30 (75) 61 (64)
 Female 10 (25) 35 (36)
Race, n (%) 0.78
 White 34 (85) 79 (88)
 Non-white 6 (15) 11 (12)
Hemoglobin, g/dl 0.14
 Median 9.5 9.0
 Range 5.5-14.4 6.0-14.7
Platelet count, ×109/l 0.96
 Median 54 49
 Range 6-376 4-323
WBC count, ×109/l 0.001
 Median 23.8 6.0
 Range 0.8-225.3 0.7-137.6
Bone marrow blasts, % <0.001
 Median 76 46
 Range 20-92 13-97
Blood blasts, % 0.006
 Median 59 28
 Range 0-98 0-99
Extramedullary involvement, n (%) 9 (24) 10 (11) 0.06
Number of chromosome abnormalities <0.001
 Median 4 9
 Range 3-15 3-33
Abbreviations: CK, complex karyotype; WBC, white blood cell.
aP-values for categorical variables are from Fisher’s exact test, P-values for continuous variables are from Wilcoxon rank sum test.
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Table 3.
Outcomes of acute myeloid leukemia patients with typical and those with atypical complex karyotype
All patients
Endpoint Atypical CK n=34 Typical CK n=83 P-valuea
Complete remission, n (%) 20 (59) 29 (35) 0.02
Disease-free survival 0.08
 Median, years 0.4 0.4
 % Disease-free at 1 year (95% CI) 30 (12-50) 3 (0-15)
 % Disease-free at 3 years (95% CI) 10 (2-27) 0
Overall survival <0.001
 Median, years 0.8 0.4
 % Alive at 1 year (95% CI) 44 (27-60) 14 (8-23)
 % Alive at 3 years (95% CI) 24 (11-39) 1 (0-6)
Patients aged <60 years
Endpoint Atypical CK n=20 Typical CK n=40 P-valuea
Complete remission, n (%) 12 (60) 15 (38) 0.11
Disease-free survival 0.05
 Median, years 0.5 0.4
 % Disease-free at 1 year (95% CI) 42 (15-67) 0
 % Disease-free at 3 years (95% CI) 17 (3-41) 0
Overall survival 0.005
 Median, years 0.9 0.6
 % Alive at 1 year (95% CI) 45 (23-65) 23 (11-36)
 % Alive at 3 years (95% CI) 25 (9-45) 3 (0-11)
Patients aged ≥60 years
Endpoint Atypical CK n=14 Typical CK n=43 P-valuea
Complete remission, n (%) 8 (57) 14 (33) 0.12
Disease-free survival 0.87
 Median, years 0.4 0.3
 % Disease-free at 1 year (95% CI) 13 (1-42) 7 (0-28)
 % Disease-free at 3 years (95% CI) 0 0
Overall survival 0.002
 Median, years 0.8 0.4
 % Alive at 1 year (95% CI) 43 (18-66) 7 (2-17)
 % Alive at 3 years (95% CI) 21 (5-45) 0
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Abbreviations: CK, complex karyotype; CI, confidence interval.
aP-values for categorical variables are from Fisher’s exact test, P-values for the time to event variables are from the log-rank test.
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